Energetic of some aliphatic amine intercalations in layered crystalline barium phenylphosphonate

Layered crystalline barium phenylphosphonate, as anhydrous Ba(HO3PC6H5)(2) or hydrated Ba(HO3PC6H5)(2)(.)2H(2)O compounds, were used as hosts for the intercalation of polar n-alkylamine molecules of the general formula H3C(CH2)(n)-NH2 (n = 1 to 5) in ethanol or 1,2-dichloroethane. The lamellar compound was calorimetrically titrated with amine in ethanol or 1,2-dichloroethane solutions at 298.15 +/- 0.20 K. The exothermic enthalpic values increased with the number of carbon atoms in the amine chain, being -4.50 +/- 0.37, -5.30 +/- 0.42, -6.77 +/- 0.21, -7.51 +/- 0.35 and -10.35 +/- 0.67 kJ mol(-1) for hydrated and -6.80 +/- 0.22, -7.75 +/- 0.37, -8.95 +/- 0.19, -9.91 +/- 0.34 and -10.82 +/- 0.56 kJ mol(-1) for anhydrous compounds, for n = 1 to 5, respectively. The favorable enthalpic processes, as a in function of the number of carbon atoms (n(c)) of the amines, expressed by Delta H degrees = - (1.22 +/- 0.12) - (1.43 +/- 0.16)n(c), and Delta H degrees = -(4.77 +/- 0.11) - (1.02 +/- 0.02)n(c) in ethanol and 1,2-dichloroethane, respectively, are more pronounced for the anhydrous compound. The spontaneity of these systems, reflected in the negative Gibbs free energies and the favorable positive entropic values, agrees with the displacement of coordinated solvent molecules as the intercalation takes place. (c) 2005 Elsevier SAS. All rights reserved.7111423142

Do people from the Jewish community prefer ancestry-based or pan-ethnic expanded carrier screening?

Ancestry-based carrier screening in the Ashkenazi Jewish population entails screening for specific autosomal recessive founder mutations, which are rarer among the general population. As it is now technically feasible to screen for many more diseases, the question arises whether this population prefers a limited ancestry-based offer or a pan-ethnic expanded carrier screening panel that goes beyond the diseases that are frequent in their own population, and is offered regardless of ancestry. An online questionnaire was completed by 145 individuals from the Dutch Jewish community (≥18 years) between April and July 2014. In total, 64.8% were aware of the existence of ancestry-based carrier screening, and respondents were generally positive about screening. About half (53.8%) preferred pan-ethnic expanded carrier screening, whereas 42.8% preferred ancestry-based screening. Reasons for preferring pan-ethnic screening included ‘everyone has a right to be tested', ‘fear of stigmatization when offering ancestry-based panels', and ‘difficulties with identifying risk owing to mixed backgrounds'. ‘Preventing high healthcare costs' was the most important reason against pan-ethnic carrier screening among those in favor of an ancestry-based panel. In conclusion, these findings show that people from the Dutch Jewish community have a positive attitude regarding carrier screening in their community for a wide range of diseases. As costs of expanded carrier screening panels are most likely to drop in the near future, it is expected that these panels will receive more support in the future